Details of the BTS
| General Information of Binding Target of SBP (BTS) (ID: ST00030) | ||||||
|---|---|---|---|---|---|---|
| BTS Name |
Fibronectin
|
|||||
| Synonyms |
FN; Cold-insoluble globulin; CIG
|
|||||
| BTS Type |
Protein
|
|||||
| Gene Name |
FN1
|
|||||
| Organism |
Homo sapiens (Human)
|
|||||
| Function |
Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization (By similarity). Participates in the regulation of type I collagen deposition by osteoblasts (By similarity).; [Anastellin]: Binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.
|
|||||
| UniProt ID | ||||||
| UniProt Entry | ||||||
| PFam | ||||||
| Gene ID | ||||||
| Sequence |
MLRGPGPGLLLLAVQCLGTAVPSTGASKSKRQAQQMVQPQSPVAVSQSKPGCYDNGKHYQ
INQQWERTYLGNALVCTCYGGSRGFNCESKPEAEETCFDKYTGNTYRVGDTYERPKDSMI WDCTCIGAGRGRISCTIANRCHEGGQSYKIGDTWRRPHETGGYMLECVCLGNGKGEWTCK PIAEKCFDHAAGTSYVVGETWEKPYQGWMMVDCTCLGEGSGRITCTSRNRCNDQDTRTSY RIGDTWSKKDNRGNLLQCICTGNGRGEWKCERHTSVQTTSSGSGPFTDVRAAVYQPQPHP QPPPYGHCVTDSGVVYSVGMQWLKTQGNKQMLCTCLGNGVSCQETAVTQTYGGNSNGEPC VLPFTYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQKYSFCTDHTVLVQTRGGNSNGALC HFPFLYNNHNYTDCTSEGRRDNMKWCGTTQNYDADQKFGFCPMAAHEEICTTNEGVMYRI GDQWDKQHDMGHMMRCTCVGNGRGEWTCIAYSQLRDQCIVDDITYNVNDTFHKRHEEGHM LNCTCFGQGRGRWKCDPVDQCQDSETGTFYQIGDSWEKYVHGVRYQCYCYGRGIGEWHCQ PLQTYPSSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIP GHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTPVTSNTVTGETTPFSP LVATSESVTEITASSFVVSWVSASDTVSGFRVEYELSEEGDEPQYLDLPSTATSVNIPDL LPGRKYIVNVYQISEDGEQSLILSTSQTTAPDAPPDTTVDQVDDTSIVVRWSRPQAPITG YRIVYSPSVEGSSTELNLPETANSVTLSDLQPGVQYNITIYAVEENQESTPVVIQQETTG TPRSDTVPSPRDLQFVEVTDVKVTIMWTPPESAVTGYRVDVIPVNLPGEHGQRLPISRNT FAEVTGLSPGVTYYFKVFAVSHGRESKPLTAQQTTKLDAPTNLQFVNETDSTVLVRWTPP RAQITGYRLTVGLTRRGQPRQYNVGPSVSKYPLRNLQPASEYTVSLVAIKGNQESPKATG VFTTLQPGSSIPPYNTEVTETTIVITWTPAPRIGFKLGVRPSQGGEAPREVTSDSGSIVV SGLTPGVEYVYTIQVLRDGQERDAPIVNKVVTPLSPPTNLHLEANPDTGVLTVSWERSTT PDITGYRITTTPTNGQQGNSLEEVVHADQSSCTFDNLSPGLEYNVSVYTVKDDKESVPIS DTIIPEVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRITVVAAGEGIPIFEDFVDSSV GYYTVTGLEPGIDYDISVITLINGGESAPTTLTQQTAVPPPTDLRFTNIGPDTMRVTWAP PPSIDLTNFLVRYSPVKNEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTP LRGRQKTGLDSPTGIDFSDITANSFTVHWIAPRATITGYRIRHHPEHFSGRPREDRVPHS RNSITLTNLTPGTEYVVSIVALNGREESPLLIGQQSTVSDVPRDLEVVAATPTSLLISWD APAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSPA SSKPISINYRTEIDKPSQMQVTDVQDNSISVKWLPSSSPVTGYRVTTTPKNGPGPTKTKT AGPDQTEMTIEGLQPTVEYVVSVYAQNPSGESQPLVQTAVTNIDRPKGLAFTDVDVDSIK IAWESPQGQVSRYRVTYSSPEDGIHELFPAPDGEEDTAELQGLRPGSEYTVSVVALHDDM ESQPLIGTQSTAIPAPTDLKFTQVTPTSLSAQWTPPNVQLTGYRVRVTPKEKTGPMKEIN LAPDSSSVVVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVSPPRRARVTDATETT ITISWRTKTETITGFQVDAVPANGQTPIQRTIKPDVRSYTITGLQPGTDYKIYLYTLNDN ARSSPVVIDASTAIDAPSNLRFLATTPNSLLVSWQPPRARITGYIIKYEKPGSPPREVVP RPRPGVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKKTDELPQLVTLPHPNLHGPE ILDVPSTVQKTPFVTHPGYDTGNGIQLPGTSGQQPSVGQQMIFEEHGFRRTTPPTTATPI RHRPRPYPPNVGEEIQIGHIPREDVDYHLYPHGPGLNPNASTGQEALSQTTISWAPFQDT SEYIISCHPVGTDEEPLQFRVPGTSTSATLTGLTRGATYNVIVEALKDQQRHKVREEVVT VGNSVNEGLNQPTDDSCFDPYTVSHYAVGDEWERMSESGFKLLCQCLGFGSGHFRCDSSR WCHDNGVNYKIGEKWDRQGENGQMMSCTCLGNGKGEFKCDPHEATCYDDGKTYHVGEQWQ KEYLGAICSCTCFGGQRGWRCDNCRRPGGEPSPEGTTGQSYNQYSQRYHQRTNTNVNCPI ECFMPLDVQADREDSRE |
|||||
| Sequence Length |
2477
|
|||||
| Synthetic Binding Protein (SBP) Targeting This BTS |
|---|
| SBP Name | Highest Status | Mechanism | Affinity | Application | Details | Ref |
|---|---|---|---|---|---|---|
| Affilin anti-FN 77405 | Research | Binder | Kd: 0.19 nM | Tumors [ICD-11: XH1N44] | [1] | |
| Anticalin anti-Fibronectin N10D | Research | Binder | Kd: 40.4 nM | Glioblastoma, primary [ICD-11: XH0MB1] | [2], [3], [4] | |
| Anticalin anti-Fibronectin N10D | Research | Binder | N.A. | Glioblastoma, primary [ICD-11: XH0MB1] | [2], [3], [4] | |
| Anticalin anti-Fibronectin N7A | Research | Binder | Kd: 5.8 nM | Glioblastoma, primary [ICD-11: XH0MB1] | [2], [3], [4] | |
| Anticalin anti-Fibronectin N7A | Research | Binder | Kd: 119 nM | Glioblastoma, primary [ICD-11: XH0MB1] | [2], [3], [4] | |
| Anticalin anti-Fibronectin N7E | Research | Binder | Kd: 7.2 nM | Glioblastoma, primary [ICD-11: XH0MB1] | [2], [3], [4] | |
| Anticalin anti-Fibronectin N7E | Research | Binder | Kd: 17 nM | Glioblastoma, primary [ICD-11: XH0MB1] | [2], [3], [4] | |
| Anticalin anti-Fibronectin N9B | Research | Binder | Kd: 39.9 nM | Glioblastoma, primary [ICD-11: XH0MB1] | [2], [3], [4] | |
| Anticalin anti-Fibronectin N9B | Research | Binder | Kd: 5.3 nM | Glioblastoma, primary [ICD-11: XH0MB1] | [2], [3], [4] | |
| Fynomer anti-FN clone D3 | Research | Binder | Kd: 85 nM | Imaging agent for patients with solid tumor; Tools for delivering of toxic agents to the tumoral vasculature | [5] | |
| scFv anti-Fn7B8 L19 | Research | Binder | Kd: 144 nM | Cancers [ICD-11: 2D4Z] | [4] | |
| scFv Radretumab | Phase II; Discontinued | Inhibitor | N.A. | Brain cancer [ICD-11: 2A00.5]; Haematological malignancies [ICD-11: 2B33.Y]; Hodgkin lymphoma [ICD-11: 2B30.Z]; Non-small cell lung cancer [ICD-11: 2C25.Y]; Solid tumour/cancer [ICD-11: 2A00-2F9Z] | [6] | |
| References |
|---|